Eduard E Zijlstra
Overview
Explore the profile of Eduard E Zijlstra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zijlstra E
Front Cell Infect Microbiol
. 2019 Aug;
9:228.
PMID: 31417876
Post-kala-azar dermal leishmaniasis (PKDL) follows visceral leishmaniasis (VL, kala-azar) in 10-60% of cases. It is characterized by an asymptomatic skin rash, usually starting in the face and consisting of macules,...
12.
Le Rutte E, Zijlstra E, de Vlas S
Trends Parasitol
. 2019 Jul;
35(8):590-592.
PMID: 31266711
Post-kala-azar dermal leishmaniasis (PKDL) is a parasitic skin infection which can occur after visceral leishmaniasis (VL). Recent xenodiagnosis studies (Mondal et al., Clin. Infect. Dis., 2018) have uncovered the infectiousness...
13.
Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, et al.
PLoS Negl Trop Dis
. 2019 Feb;
13(2):e0007132.
PMID: 30789910
Background: The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is low. Although use...
14.
Diro E, Blesson S, Edwards T, Ritmeijer K, Fikre H, Admassu H, et al.
PLoS Negl Trop Dis
. 2019 Jan;
13(1):e0006988.
PMID: 30653490
Background: Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of...
15.
Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, et al.
Clin Microbiol Rev
. 2018 Aug;
31(4).
PMID: 30158301
Research in visceral leishmaniasis in the last decade has been focused on how better to use the existing medicines as monotherapy or in combination. Systematic research by geographical regions has...
16.
den Boer M, Das A, Akhter F, Burza S, Ramesh V, Ahmed B, et al.
Clin Infect Dis
. 2018 Mar;
67(5):667-675.
PMID: 29554244
Background: A safe and effective short-course treatment regimen for post-kala-azar dermal leishmaniasis (PKDL) is considered essential for achieving and sustaining elimination of visceral leishmaniasis (VL) in the Indian subcontinent [1,...
17.
Zijlstra E, Alves F, Rijal S, Arana B, Alvar J
PLoS Negl Trop Dis
. 2017 Nov;
11(11):e0005877.
PMID: 29145397
Background: The South-East Asia Region Kala-azar Elimination Programme (KAEP) is expected to enter the consolidation phase in 2017, which focuses on case detection, vector control, and identifying potential sources of...
18.
French N, Gordon S, Mwalukomo T, White S, Mwafulirwa G, Longwe H, et al.
Malawi Med J
. 2016 Nov;
28(3):115-122.
PMID: 27895845
Background: is a leading and serious coinfection in adults with human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this disease by vaccination with the current 23-valent polysaccharide vaccine...
19.
Zijlstra E
Parasit Vectors
. 2016 Aug;
9:464.
PMID: 27553063
Post-kala-azar dermal leishmaniasis (PKDL) is a common complication of visceral leishmaniasis (VL) caused by Leishmania donovani. Because of its possible role in transmission it is considered a public health problem...
20.
Zijlstra E
Arch Dis Child
. 2016 Feb;
101(6):561-567.
PMID: 26895806
Visceral leishmaniasis (VL or kala-azar) is most endemic in Asia and Africa and commonly affects young children. It is usually caused by Leishmania donovani or Leishmania infantum that are transmitted...